MTATP6P27

Across TCGA pan-cancer cohorts, MTATP6P27 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated MTATP6P27 data layer.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MTATP6P27 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTATP6P27 expression acts as an unfavorable survival marker, although some lineages such as CHOL and HNSC show a favorable association.

KIRC, MESO, and CHOL are the cancer types where MTATP6P27 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.399	0.628	<.001	115	view →
MESO	OS	Tertile	All	0.354	0.594	<.001	61	view →
CHOL	OS	Median	All	0.892	0.548	.005	32	view →
HNSC	DFS	Quartile	IV	0.772	0.546	.003	26	view →
LIHC	DFS	Tertile	All	0.422	0.603	<.001	25	view →
ESCA	OS	Quartile	All	0.287	1.000	.009	24	view →
BLCA	OS	Quartile	All	0.742	0.571	.014	19	view →
PCPG	DFS	Median	All	0.516	0.884	.009	15	view →
LAML	DFS	Tertile	All	0.518	0.290	.014	10	view →
OV	OS	Median	IV	0.470	0.309	.014	10	view →
CESC	OS	Median	All	0.848	0.740	.008	10	view →
LUAD	DFS	Median	IV	0.316	0.753	.012	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

MTATP6P27–KIRC (OS)

Open the KIRC breakdown →